4//SEC Filing
Leavitt Chase C. 4
Accession 0001209191-23-052023
CIK 0001260990other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 5:01 PM ET
Size
25.3 KB
Accession
0001209191-23-052023
Insider Transaction Report
Form 4
Leavitt Chase C.
General Counsel/Secretary
Transactions
- Award
Stock Option
2023-10-02+55,519→ 55,519 totalExercise: $0.31Exp: 2032-01-20→ Common Stock (55,519 underlying) - Disposition to Issuer
Stock Option
2023-10-02−65,000→ 0 totalExercise: $6.46Exp: 2031-04-29→ Common Stock (65,000 underlying) - Disposition to Issuer
Stock Option
2023-10-02−55,519→ 0 totalExercise: $1.94Exp: 2032-01-20→ Common Stock (55,519 underlying) - Award
Stock Option
2023-10-02+65,000→ 65,000 totalExercise: $0.31Exp: 2031-04-29→ Common Stock (65,000 underlying) - Award
Stock Option
2023-10-02+28,750→ 28,750 totalExercise: $0.31Exp: 2032-07-28→ Common Stock (28,750 underlying) - Award
Stock Option
2023-10-02+235,000→ 235,000 totalExercise: $0.31Exp: 2033-10-02→ Common Stock (235,000 underlying) - Disposition to Issuer
Stock Option
2023-10-02−28,750→ 0 totalExercise: $1.04Exp: 2032-07-28→ Common Stock (28,750 underlying) - Disposition to Issuer
Stock Option
2023-10-02−210,000→ 0 totalExercise: $0.96Exp: 2033-02-21→ Common Stock (210,000 underlying) - Award
Stock Option
2023-10-02+210,000→ 210,000 totalExercise: $0.31Exp: 2033-02-21→ Common Stock (210,000 underlying)
Footnotes (8)
- [F1]25% of the shares subject to the option ("Option Shares") vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
- [F2]On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged.
- [F3]25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
- [F4]50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).
- [F5]25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service.
- [F6]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised.
- [F7]The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised.
- [F8]25% of the Option Shares vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. The option may not be exercised if recipient's employment or service terminates prior to October 2, 2024 other than as a result of a Qualifying Termination. All of the Option Shares vest and become exercisable in the event of a Change in Control.
Documents
Issuer
Oncternal Therapeutics, Inc.
CIK 0001260990
Entity typeother
Related Parties
1- filerCIK 0001777467
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 5:01 PM ET
- Size
- 25.3 KB